REPLIMUNE GROUP, INC. Revenue
REPLIMUNE GROUP, INC. (REPL) reported Revenue of $0 for the 9-month period ending 2018-12-31, per its 10-Q filed 2019-02-14.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2019-02-14
- REPLIMUNE GROUP, INC. revenues for the quarter ending 2018-12-31 was $0.00.
- REPLIMUNE GROUP, INC. revenues for the quarter ending 2018-09-30 was $0.00.
- REPLIMUNE GROUP, INC. revenues for the quarter ending 2018-06-30 was $0.00.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month |
|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-02-14 | $0.00 derived: sum of 2 quarters · filed 2019-02-14 | $0.00 10-Q · filed 2019-02-14 |
| 2018-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-11-14 | $0.00 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |